The FDA has placed multiple investigational gene therapy clinical trials on hold, signaling broader platform concerns.

Reeling from the deaths of two patients who took Duchenne muscular dystrophy gene therapy Elevidys, Sarepta is launching a ...

Sarepta Therapeutics appears to have right-sized itself after laying off over a third of its staff, announcing a significant ...

On an investor call Friday, analysts grilled the company over its apparent lack of transparency on the matter.

In a letter to the patient advocacy group World Duchenne Organization on Monday, Roche (OTCQX:RHHBF) said that the EMA has requested a temporary hold on several clinical trials involving Elevidys ...

Sarepta Therapeutics recently demanded a prominent patient advocacy organization censor a video that contained pointed criticism of the company, STAT has learned.

Sarepta Therapeutics (SRPT) stock drops as the EU officials request a clinical hold on trials involving its gene therapy Elevidys after a patient death. Read more here.

Sarepta Therapeutics on Sunday said there had been a second reported case of acute liver failure resulting in death after a patient received the company's gene therapy for a rare form of muscular ...

Sarepta Therapeutics said on Tuesday that a 16-year-old boy died from acute liver failure months after receiving the company's U.S-approved gene therapy for a rare muscular dystrophy.

Sarepta posted a deeper-than-expected Q1 loss and cut its 2025 forecast due to Elevidys rollout delays, despite beating revenue estimates.

Sarepta Therapeutics celebrated the results of a clinical trial of its Duchenne therapy. The rest of the Duchenne community was more cautious in its enthusiasm.